Nav: Home

Repurposed quinacrine synergizes with cisplatin, reducing the effective dose required for treatment

October 11, 2019

The authors have developed the Accelera TED platform to repurpose drugs for HNSCC treatment; using in vitro assays and in vivo models.

Screening a library of clinically-approved drugs identified the anti-malarial agent quinacrine as a candidate, which significantly reduced viability in a concentration dependent manner in five HNSCC cell lines and in six primary HNSCC samples.

In vivo, daily treatment with 100 mg/kg oral quinacrine plus cisplatin significantly inhibited tumor outgrowth, extending median time to reach maximum tumor volume from 20 to 32 days versus control, and from 28 to 32 days versus 2 mg/kg cisplatin alone.

Dr. Hisham Mehanna and Dr. Nikolaos Batis said, "Head and neck squamous cell carcinoma is a debilitating disease comprising 600,000 cases per year worldwide"

Due to the high morbidity of current treatments, quality of life is severely impaired, with evident unmet need necessitating more effective therapies with lower toxicity; especially as recent studies examining cetuximab as a less toxic alternative for low risk human papillomavirus positive HNSCC have shown similar toxicity, and lower efficacy compared to cisplatin.

On initial screening against HNSCC cell lines, quinacrine was identified as a potential hit.

Quinacrine is a potent late-stage autophagy inhibitor and has been shown to prime cells to the effects of cisplatin via apoptosis in cervical and endometrial cancer.

Further mechanistic insights have been demonstrated in HNSCC whereby quinacrine was able to restore the function of the tumor suppressive protein, tumor protein 53, leading to enhanced capabilities of initiating apoptotic cell death following DNA damage with cisplatin chemotherapy; Moreover, quinacrine treatment has been shown to suppress phosphoinositide 3-kinase, protein kinase B, mechanistic target of rapamycin and nuclear factor kappa-light-chain-enhancer of activated B cells pathways.

The Mehanna/Batis Research team concluded, "Notably, our study is the first to demonstrate that quinacrine is able to reduce tumor burden in mice bearing HNSCC xenograft tumors, using concentrations that are clinically relevant."
-end-
Full text - http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=27156&path%5B%5D=86845

Correspondence to - Hisham Mehanna - h.mehanna@bham.ac.uk and Nikolaos Batis - n.batis@bham.ac.uk

Keywords - head and neck cancer, drug repurposing, drug repositioning, quinacrine, mepacrine

About Oncotarget

Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

Oncotarget is published by Impact Journals LLC.

To learn more about Oncotarget, please visit http://www.ImpactJournals.com

Impact Journals LLC

Related Cisplatin Articles:

Repurposed quinacrine synergizes with cisplatin, reducing the effective dose required for treatment
The authors have developed the Accelera TED platform to repurpose drugs for HNSCC treatment; using in vitro assays and in vivo models.
Response rate to albumin-bound paclitaxel plus gemcitabine plus cisplatin treatment among patients with advanced pancreatic cancer: A phase 1b/2 pilot clinical trial
Published today in the Journal of the American Medical Association (JAMA) Oncology, researchers at HonorHealth Research Institute and TGen, an affiliate of City of Hope, found that among a clinical trial of 25 patients, adding the drug cisplatin to a current standard-of-care drug regimen resulted in substantial tumor shrinkage for 71 percent of those patients, and dramatically increased survival beyond one year.
Reduced-dose IMRT w/ cisplatin meets predetermined benchmarks for PFS and swallowing-related QOL
Results of the NRG Oncology clinical trial NRG-HN002 indicated that the combination of intensity-modulated radiotherapy (IMRT) and cisplatin was able to meet acceptability criteria for progression-free survival (PFS) and swallowing-related quality of life for patients who have p16-positive, non-smoking-associated oropharyngeal cancer.
Researchers clock DNA's recovery time after chemotherapy
A team of researchers led by Nobel laureate Aziz Sancar found that DNA damaged by the widely used chemotherapy drug cisplatin is mostly good as new in noncancerous tissue within two circadian cycles, or two days.
Drug makes tumors more susceptible to chemo
Researchers at MIT and Duke University have discovered a potential drug compound that can block a mutagenic DNA repair pathway that helps cancer cells survive chemotherapy.
Chemotherapeutic drugs and plasma proteins: Exploring new dimensions
This review provides a bird's eye view of interaction of a number of clinically important drugs currently in use that show covalent or non-covalent interaction with serum proteins.
Radiation/cisplatin combination established as standard of care for HPV+ oral cancer
Combinations of radiation and chemotherapy drugs have been shown to cure HPV-related head and neck cancer with a high success rate.
RUDN biochemists found out how ROS affect cisplatin resistance in ovarian cancer cells
A team of sciences from RUDN Institute of Medicine found out how reactive oxygen species affect the resistance of ovarian cancer cells to chemotherapy on the example of cisplatin -- an antitumor drug used to treat this type of malignant growth.
Overcoming resistance to a standard chemotherapy drug
Winship researchers identified an enzyme responsible for making tumors and cancer cell lines resistant to cisplatin, along with an experimental drug, lestaurtinib, which targets that enzyme.
Colorado study suggests new combination treatment against relapsed head and neck cancer
'EphB4-ephrin-B2 inhibitors are currently in clinical trials in other disease settings, and our work shows that it might be successful in combination with EGFR inhibition in advanced head and neck cancers as well,' says Sana Karam, M.D., Ph.D.
More Cisplatin News and Cisplatin Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.